- Home
- LYFT vs MDGL Comparison
LYFT vs MDGL Comparison
Compare LYFT & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYFT
- MDGL
- Stock Information
- Founded
- LYFT 2007
- MDGL 2011
- Country
- LYFT United States
- MDGL United States
- Employees
- LYFT N/A
- MDGL N/A
- Industry
- LYFT Business Services
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- LYFT Consumer Discretionary
- MDGL Health Care
- Exchange
- LYFT Nasdaq
- MDGL Nasdaq
- Market Cap
- LYFT 6.7B
- MDGL 6.1B
- IPO Year
- LYFT 2019
- MDGL N/A
- Fundamental
- Price
- LYFT $22.84
- MDGL $417.43
- Analyst Decision
- LYFT Buy
- MDGL Strong Buy
- Analyst Count
- LYFT 30
- MDGL 10
- Target Price
- LYFT $17.63
- MDGL $474.67
- AVG Volume (30 Days)
- LYFT 24.9M
- MDGL 329.8K
- Earning Date
- LYFT 11-05-2025
- MDGL 10-30-2025
- Dividend Yield
- LYFT N/A
- MDGL N/A
- EPS Growth
- LYFT N/A
- MDGL N/A
- EPS
- LYFT 0.22
- MDGL N/A
- Revenue
- LYFT $6,111,324,000.00
- MDGL $515,547,000.00
- Revenue This Year
- LYFT $15.07
- MDGL $394.12
- Revenue Next Year
- LYFT $13.76
- MDGL $57.74
- P/E Ratio
- LYFT $103.34
- MDGL N/A
- Revenue Growth
- LYFT 19.94
- MDGL 3421.98
- 52 Week Low
- LYFT $9.66
- MDGL $200.63
- 52 Week High
- LYFT $23.50
- MDGL $457.16
- Technical
- Relative Strength Index (RSI)
- LYFT 81.90
- MDGL 54.19
- Support Level
- LYFT $18.30
- MDGL $418.36
- Resistance Level
- LYFT $20.50
- MDGL $440.90
- Average True Range (ATR)
- LYFT 0.95
- MDGL 13.63
- MACD
- LYFT 0.47
- MDGL -5.66
- Stochastic Oscillator
- LYFT 91.68
- MDGL 4.56
About LYFT Lyft Inc.
Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft has entered the bike- and scooter-share market to bring multimodal transportation options to users.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.